Methylated Biomarkers Predictive of Endometrial Cancer Risk

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT06800677

Acronym

BioMEC

Enrollment

200

Registered

2025-01-30

Start date

2024-07-31

Completion date

2026-12-31

Last updated

2025-01-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Endometrial Cancer

Keywords

risk, prevention, prediction

Brief summary

The goal of this observational study is to identify endometrial cancer risk predictive biomarkers and to optimise the methodology for their detection and quantification in non-invasive samples.

Interventions

PROCEDUREHysterectomy

Elective hysterectomy

Study design

Observational model

CASE_CONTROL

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

FEMALE

Age

45 Years to 70 Years

Healthy volunteers

Inclusion criteria

1. Women aged 45-70 years 2. Attending St Mary's Hospital, Manchester for an elective hysterectomy by any route for either the treatment of endometrial cancer or a benign gynaecological condition 3. Able to consent to participation in the study

Exclusion criteria

1. Presence of malignancy asides from endometrial cancer 2. Undergoing elective hysterectomy for suspected ovarian cancer

Design outcomes

Primary

Measure	Time frame
Sensitivity, specificity, negative and positive predictive value of single gene methylation classifiers in predicting the presence of endometrial cancer in minimally- and invasive samples	1 day

Secondary

Measure	Time frame
Sensitivity, specificity, positive and negative predictive value of a multi-gene methylation classifier for predicting the presence of endometrial cancer	1 day

Countries

United Kingdom

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026